- Home
- KNSA vs TARS Comparison
KNSA vs TARS Comparison
Compare KNSA & TARS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KNSA | TARS |
|---|---|---|
| Founded | 2015 | 2016 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.8B |
| IPO Year | 2018 | 2020 |
Fundamental Metrics
Financial Performance| Metric | KNSA | TARS |
|---|---|---|
| Price | $41.52 | $80.77 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 9 |
| Target Price | $51.33 | ★ $76.56 |
| AVG Volume (30 Days) | 345.4K | ★ 419.7K |
| Earning Date | 10-28-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.47 | N/A |
| Revenue | ★ $597,973,000.00 | $366,100,000.00 |
| Revenue This Year | $62.63 | $147.24 |
| Revenue Next Year | $29.93 | $53.11 |
| P/E Ratio | $89.09 | ★ N/A |
| Revenue Growth | 55.68 | ★ 182.44 |
| 52 Week Low | $17.82 | $38.51 |
| 52 Week High | $42.98 | $85.25 |
Technical Indicators
Market Signals| Indicator | KNSA | TARS |
|---|---|---|
| Relative Strength Index (RSI) | 55.74 | 59.14 |
| Support Level | $40.33 | $78.10 |
| Resistance Level | $42.32 | $83.34 |
| Average True Range (ATR) | 1.45 | 3.12 |
| MACD | -0.13 | -0.39 |
| Stochastic Oscillator | 56.68 | 42.64 |
Price Performance
Historical ComparisonAbout KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.
About TARS Tarsus Pharmaceuticals Inc.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.